Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. by Keymeulen, B, Walter, M, Mathieu, C, Kaufman, L, Gorus, F, Hilbrands, R, Vandemeulebroucke, E, Van de Velde, U, Crenier, L, De Block, C, Candon, S, Waldmann, H, Ziegler, A, Chatenoud, L, Pipeleers, D

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. by Keymeulen, B, Candon, S, Fafi-Kremer, S, Ziegler, A, Leruez-Ville, M, Mathieu, C, Vandemeulebroucke, E, Walter, M, Crenier, L, Thervet, E, Legendre, C, Pierard, D, Hale, G, Waldmann, H, Bach, J, Seigneurin, J, Pipeleers, D, Chatenoud, L

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. by Keymeulen, B, Vandemeulebroucke, E, Ziegler, A, Mathieu, C, Kaufman, L, Hale, G, Gorus, F, Goldman, M, Walter, M, Candon, S, Schandene, L, Crenier, L, De Block, C, Seigneurin, J, De Pauw, P, Pierard, D, Weets, I, Rebello, P, Bird, P, Berrie, E, Frewin, M, Waldmann, H, Bach, J, Pipeleers, D, Chatenoud, L